A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

What Was Tested

In this phase 2 trial, researchers set out to test Retatrutide.

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).

The study will last around 31 weeks.

It had two arms (groups): Retatrutide (experimental) and Placebo (placebo comparator).

Participants will receive LY3437943.

The registry classes the interventions as drug.

Who Took Part

146 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²). Have been diagnosed with chronic kidney disease (CKD).

The full record lists 5 inclusion and 6 exclusion criteria; among the exclusions: have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening; have a prior or planned surgical treatment for obesity; have type 1 diabetes (t1d).

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Because people in this Retatrutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Retatrutide.

Those kept unaware of assignments: participant and investigator.

It started in 2023-07-20 with completion listed for 2025-10-01.

It ran at 42 sites in United States (19), Canada (9), United Kingdom (7), Italy (4) and Spain (3).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change from Baseline in Glomerular Filtration Rate (mGFR) (time frame: Baseline, Week 24).

It also tracked 17 secondary outcomes, for example Change from Baseline in Urine Albumin-to-Creatinine Ratio (UACR), Change from Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa), Change from Baseline in Filtration Fraction Estimated from Measured Glomerular Filtration Rate (mGFR), Change from Baseline in Renal Mean Arterial Flow as Assessed by Magnetic Resonance Imaging (MRI), Corrected by Hematocrit, Change from Baseline in in Mean Arterial Flow (MAF) and Change from Baseline in Renal Artery Resistive Index (RARI).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Retatrutide in 146 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Retatrutide compound page, all human trials.